This study aimed to understand recent decisions and recommendations for novel oncology medications by HTA agencies in Latin America and compare important characteristics with corresponding appraisals issued in Canada and the UK. While healthcare systems, health policy priorities, and implementation of HTA processes vary between countries, HTA appraisals from various agencies for a product in a specific indication are often centered on similar clinical trial evidence and country-specific economic data submitted by manufacturers. ![]() ![]() RESEARCH PODIUM PRESENTATIONS CANCER STUDIES CA1: COMPARATIVE ASSESSMENT OF LATIN AMERICAN HTA APPRAISALS FOR ONCOLOGY Arvin-Berod C1, Benjamin N2, Martel M3,1Xcenda Switzerland GmbH, Bern, Switzerland, 2Xcenda, LLC, Palm Harbor, FL, USA, 3Xcenda (UK) Ltd, London, UK OBJECTIVES: In the last decade, Health Technology Assessment (HTA) organisations in Latin America have continued to evolve as key stakeholders in the healthcare decision-making continuum.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |